Article
Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 May 2003
Cohen Victor, Panet-Raymond Valerie, Sabbaghian Nelly, Morin Isabelle, Batist Gerald, Rozen Rima
Abstract excerpt
PURPOSE: Fluorouracil (5-FU) is widely used in the treatment of colorectal cancer. Methylenetetrahydrofolate reductase (MTHFR) could play an important role in the action of 5-FU, an inhibitor of thymidylate synthetase, by converting 5,10-methylenetetrahydrofolate, a substrate of thymidylate synthetase, to 5-methyltetrahydrofolate. A polymorphism in MTHFR (677 C-->T; A222V) reduces enzyme activity and presumably...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
